These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29702096)

  • 1. Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration.
    Larsen LK; Jakobsen JS; Abdul-Al A; Guldberg P
    J Urol; 2018 Oct; 200(4):749-757. PubMed ID: 29702096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
    Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
    J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
    Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
    J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
    Gonzalgo ML; Pavlovich CP; Lee SM; Nelson WG
    Clin Cancer Res; 2003 Jul; 9(7):2673-7. PubMed ID: 12855646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
    Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
    Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
    Baden J; Adams S; Astacio T; Jones J; Markiewicz J; Painter J; Trust C; Wang Y; Green G
    J Urol; 2011 Nov; 186(5):2101-6. PubMed ID: 21944123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
    Rogers CG; Yan G; Zha S; Gonzalgo ML; Isaacs WB; Luo J; De Marzo AM; Nelson WG; Pavlovich CP
    J Urol; 2004 Oct; 172(4 Pt 1):1501-3. PubMed ID: 15371879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.
    Meid FH; Gygi CM; Leisinger HJ; Bosman FT; Benhattar J
    J Urol; 2001 May; 165(5):1802-5. PubMed ID: 11342979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
    Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
    Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
    Rouprêt M; Hupertan V; Yates DR; Catto JW; Rehman I; Meuth M; Ricci S; Lacave R; Cancel-Tassin G; de la Taille A; Rozet F; Cathelineau X; Vallancien G; Hamdy FC; Cussenot O
    Clin Cancer Res; 2007 Mar; 13(6):1720-5. PubMed ID: 17363525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
    Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
    Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter evaluation of an investigational prostate cancer methylation assay.
    Baden J; Green G; Painter J; Curtin K; Markiewicz J; Jones J; Astacio T; Canning S; Quijano J; Guinto W; Leibovich BC; Nelson JB; Vargo J; Wang Y; Wuxiong C
    J Urol; 2009 Sep; 182(3):1186-93. PubMed ID: 19625061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.
    Nakai Y; Miyake M; Anai S; Hori S; Tatsumi Y; Morizawa Y; Onisi S; Tanaka N; Fujimoto K
    Lasers Med Sci; 2018 Sep; 33(7):1557-1563. PubMed ID: 29725946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.
    Garcia-Reyes K; Nguyen HG; Zagoria RJ; Shinohara K; Carroll PR; Behr SC; Westphalen AC
    J Urol; 2018 Mar; 199(3):699-705. PubMed ID: 28941918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.